CLL BTKi Therapy: FAQ Part 3
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 3

Released: September 17, 2020

Expiration: September 16, 2021

Danielle M. Brander
Danielle M. Brander, MD
Jeffrey P. DONOTUSESharman
Jeffrey P. DONOTUSESharman, MD
Jeff DONOTUSESharman
Jeff DONOTUSESharman, MD
Nicole Lamanna
Nicole Lamanna, MD

Activity

Progress
1
Course Completed

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:

  • The impact of COVID-19 on CLL treatment decisions
  • The use of anti-CD20 antibodies in combination with BTK inhibitors
  • Considerations when recommending BTK inhibitors
  • MRD testing in patients with CLL
  • The potential impact of targeted therapies on when to start treatment

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program, including associated downloadable slidesets: https://www.clinicaloptions.com/oncology/programs/cll-horizons